Rallybio Acquisition of Candid Therapeutics Targets Growth in the Rare Disease Sector
Rallybio Corporation has officially entered into a definitive agreement to acquire Candid Therapeutics in an all-stock transaction designed to bolster its clinical
by 
Josh Weiner
Josh Weiner